Featured News

The FDA hosted the Gastroenterology Regulatory Endpoints and the Advancement of Therapeutics VI (GREAT VI) Workshop on Celiac Disease - the second workshop ever held by the FDA for celiac disease.

As members of the Consumers United for Evidence-based Healthcare, the Celiac Disease Foundation invites you to join us at the Virtual 2021 CUE Annual Membership Meeting: Bridging the Gap between Evidence and Action: Implications for Health Equity.

Researchers at Boston Children’s Hospital are evaluating access to gluten-free food prior to and during the COVID-19 pandemic. We invite anyone with celiac disease following a gluten-free diet to complete this 3-5 minute survey.

Periodically, the FDA hosts workshops to help researchers understand exactly what the FDA will be looking for (aka “endpoints”) when evaluating the efficacy of a proposed drug.

Researchers at MassGeneral Hospital for Children have found substantial gut microbiome changes in the intestines of at-risk infants before celiac disease onset.

ZED1227, an experimental drug was found to be able to prevent intestinal damage in a preliminary trial of 163 adults with celiac disease.

The overall prevalence of celiac disease was found to be 1.6% - a much greater percentage than the 1% that researchers have been approximating for years.

A recent study published in JAMA Network, using two decades worth of dietary data, concluded that gluten consumption in people without celiac disease did not impair cognitive function.

Each year, we look forward to May Celiac Awareness Month for the chance to celebrate our community’s tireless work.

The CeDLara Study is for adults who have been diagnosed with celiac disease and are still experiencing symptoms despite following a gluten-free diet.